Alemtuzumab, a monoclonal antibody directed against human CD52, is used in the treatment of MS. To characterize the impact of anti-CD52 administration, a monoclonal antibody to mouse CD52 (anti-muCD52) was generated and evaluated in EAE mouse models of MS. A single course of anti-muCD52 provided a therapeutic benefit accompanied by a reduction in the frequency of autoreactive T lymphocytes and production of pro-inflammatory cytokines. Examination of the CNS revealed a decrease in infiltrating lymphocytes, demyelination and axonal loss. Electrophysiological assessment showed preservation of axonal conductance in the spinal cord. These findings suggest that anti-CD52 therapy may help preserve CNS integrity.
Multiple sclerosis (MS) is a chronic, autoimmune disorder of the central nervous system (CNS) leading to demyelination and associated neurological symptoms.
The exact etiology of MS remains unclear but is generally believed to involve a combination of genetic and environmental factors that lead to the development of CNS autoimmunity and progression of disease in susceptible individuals. Experimental and clinical data suggest that in MS, peripheral activation of T cells reactive against CNS antigens results in upregulation of adhesion molecules and ability of the T cells to cross the blood-brain barrier. Once in the CNS, autoreactive T cells are activated locally by CNS antigens and cause inflammation and damage through the release of pro-inflammatory cytokines and chemokines that recruit and activate other effector cells (e.g. macrophages) (Friese et al., 2014) . B lymphocytes are also postulated to participate in disease pathogenesis through the production of autoantibodies, presentation of CNS antigens to T lymphocytes and/or production of cytokines (Krumbholz et al., 2012) . But perhaps the strongest evidence for a pathogenic role of lymphocytes in MS is the observed efficacy of disease-modifying therapies targeted at T and/or B cells.
Over the past few years, a number of therapies designed to inhibit the proliferation, function or migration of T lymphocytes have been approved for the treatment of RRMS (Ransohoff et al., 2015) . Recent clinical trial data with B cell depleting agents (rituximab, ocrelizumab) also suggest that targeting B lymphocytes may provide a clinical benefit thus supporting a role of B lymphocytes in MS disease pathogenesis (Castillo-Trivino et al., 2013) . Alemtuzumab, a humanized monoclonal antibody that targets both T and B lymphocytes was recently approved in over 40 countries. Alemtuzumab is specific for CD52, an antigen present at high levels on the surface of T and B lymphocytes and at lower levels on other immune cells (Hale et al., 1990; Rao et al., 2012) . Pivotal phase 3 trials conducted in treatment-naïve relapsing-remitting (RRMS) patients (CARE-MS I) and in RRMS patients who relapsed on prior therapy (CARE-MS II) indicated that alemtuzumab administered as two annual courses of treatment (12 mg intravenously on 5 consecutive days at study start and 3 days a year later) provided superior efficacy compared to interferon-β1a (IFN-β1a) administered three times per week (44 μg subcutaneously) Coles et al., 2012a) . In addition, long-term follow-up of patients from a phase 2 study (CAMMS223) suggested that alemtuzumab provides a durable benefit as it lowered the risk of sustained accumulation of disability by 72% and the rate of relapse by 69% compared to IFNβ-1a out to 4 years after the last alemtuzumab treatment (Coles et al., 2012b) . The mechanism by which alemtuzumab exerts its therapeutic effect in MS is not fully understood but may involve rebalancing of the immune system through the depletion and repopulation of lymphocytes. In clinical studies, the administration of alemtuzumab results in rapid depletion of lymphocytes from the circulation which may reduce the inflammatory processes associated with MS (Cox et al., 2005; Thompson et al., 2010) . This is followed by a prolonged period of lymphocyte repopulation and clinical research findings suggest that the number, proportions and properties of lymphocyte subsets are altered during the repopulation process. An enrichment in regulatory T (Treg) cells as well as a shift in the CD4 + T cell cytokine profile, characterized by a decrease in the production of pro-inflammatory cytokines and an increase in antiinflammatory cytokines, have been observed in repopulating lymphocytes post-alemtuzumab (Cox et al., 2005; Zhang et al., 2013) . Such changes may lead to a rebalancing of the immune system that persists long after clearance of the antibody and which may contribute to the observed long-lived therapeutic benefit in MS patients. While studies in MS patients have allowed characterization of the impact of alemtuzumab on blood lymphocyte populations and on CNS parameters via imaging, mouse models afford the opportunity to collect tissues not accessible in humans and allow for the conduct of additional in vivo assays to further our understanding of the mechanism of action and effects of anti-CD52 treatment. In previous studies, we took advantage of the ability to perform immunological challenges and collect lymphoid organs in the mouse to conduct an in-depth characterization of the functionality of the immune system following treatment with anti-CD52 (Hu et al., 2009; Turner et al., 2013) . In the current studies, the impact of anti-CD52 therapy was evaluated in mouse models of experimental autoimmune encephalomyelitis (EAE) with a particular focus on the CNS compartment.
Materials and methods

Anti-mouse CD52 monoclonal antibody
Anti-mouse CD52 (muCD52) monoclonal antibodies were generated by immunizing human CD52 knock-in/murine CD52 knockout mice. Animals received three subcutaneous (s.c.) immunizations with a muCD52 peptide (GQATTAASGTNKNSTSTKKTPLKS) conjugated to keyhole limpet hemocyanin (KLH) emulsified in Titermax Gold (Sigma-Aldrich; St. Louis, MO) followed by intraperitoneal (i.p.) immunization with wild type C57BL/6 mouse splenocytes as a source of naturally occurring CD52. Four days prior to the collection of spleen cells, animals were rechallenged i.p. with muCD52-KLH peptide and the following day with the same peptide-KLH intravenously (i.v.). Spleen cells were fused to SP0/2 cells to generate monoclonal antibodies, serum titers assessed by peptide and/or muCD52 fusion protein-based ELISA, and clones screened for muCD52 specificity by flow cytometry. The characteristics of the clone selected for these studies are described in Section 3.1.
Experimental autoimmune encephalomyelitis (EAE) mouse models
All experimental procedures were approved by and performed in accordance with the Genzyme Institutional Animals Care and Use Committee (IACUC) and conducted in Genzyme's Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility. EAE was induced by immunizing C57BL/6ByJ and SJLByJ mice (Jackson Laboratories Bar Harbor, ME) s.c. with 200 μg of MOG , MOG 1-121 , or PLP 131-153 peptides emulsified in complete Freund's adjuvant (Chondrex, Redmond, WA) containing 4 mg/ml Mycobacterium tuberculosis (Stromnes and Goverman, 2006) . Pertussis toxin (200 ng: SigmaAldrich; St. Louis, MO) was given i.v. on days 0 and 2. Clinical symptoms of EAE were evaluated using a 5 point scale as follows: 0 no clinical disease, 1.0 complete tail paralysis, 2.0 tail paralysis with hind limb weakness, 3.0 hind limb paralysis, 4.0 hind limb paralysis and fore limb weakness, 5.0 moribund/death. Vehicle (phosphate-buffered saline: ThermoFisher Scientific Inc., Waltham, MA) or anti-muCD52 treatment was given s.c. for five consecutive days as described in each individual figure legend. A dose level of 10 mg/kg of anti-muCD52 was selected based on its ability to achieve levels of lymphocyte depletion and kinetics of repopulation comparable to those observed with alemtuzumab administration in human CD52 transgenic mice (Hu et al., 2009; Turner et al., 2013) and patients.
Flow cytometry analysis of immune cell populations and cytokine expression
Quantitation of lymphocyte populations from the spleen and peripheral blood was performed by flow cytometry analysis of single cell suspensions as previously described (Turner et al., 2013) . Isolation of resident CNS (brain and spinal cord) lymphocytes was performed as described (Rothhammer et al., 2011) . Briefly, CNS tissue from perfused animals was digested with collagenase and DNAse followed by mononuclear cell separation by Percoll density gradient centrifugation (Sigma-Aldrich; St. Louis, MO). Mononuclear cells were collected and used for flow cytometry analysis. Staining of immune cells was performed by incubating 1 × 10 6 cells with fluorescently-labeled antibodies against mouse cell surface markers including CD4 (RM4-5), CD8 (53-6.7) CD44 (1M7), CD62L (Mel-14), CD25 (PC61.5), FR4 (12A5), B220 (RA3-6B2), NK1.1 (PK136), and, GR-1 (RB6.8C5) purchased from Ebioscience (San Diego, CA) or BD Bioscience (San Jose, CA). Peripheral blood was evaluated by staining 50 μl of whole blood with the indicated antibodies followed by removal of contaminating red blood cells with FACs lysis buffer (BD Bioscience) as described by the manufacturer. Fluorescence intensities were determined using an LSR-II flow cytometer (BD Bioscience) and data analysis was performed using Flowjo software (Treestar Inc., Ashland, OR). Quantitation of absolute numbers of specific cell populations in the spleen and CNS was determined by multiplying the percentage of the FACS-identified cellular population by the total number of cells present in each organ. Numbers of specific cell populations per microliter of peripheral blood were quantified using Countbright Absolute Counting Beads (Invitrogen Life Technologies, Grand Island, NY) as described by the manufacturer (number of cells/μl = number of cells counted / number of beads counted × number of beads added). Percent control for all tissues was calculated by dividing the number of total cells for each population by the mean total number of the same cellular population from the vehicle-treated control group [total cells in test animal/mean of total cells in control group × 100].
Intracellular cytokine staining was performed by culturing splenocytes in vitro with 1 μg/ml of MOG 35-55 peptide for 5 h in the presence of GolgiStop (BD Bioscience; San Jose, CA) as described by the manufacturer. Cells were co-stained with anti-CD4, anti-IFNγ and anti-IL-17 antibodies (Ebioscience, San Diego, CA).
Levels of cytokine release were evaluated by culturing splenocytes in vitro for 48 h with 1 μg of MOG 35-55 peptide or irrelevant peptide (Ova 323-339 ). Supernatants were then collected and analyzed for IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, IFNγ and TNFα using an Aushon multiplex array (Aushon Biosystems, Billerica, MA) following the manufacturer's instructions.
Immunohistochemistry
Spinal cord tissue samples were processed and sectioned by Mass Histology (Worcester, MA). Tissues were processed using a standard protocol consisting of formalin fixation and paraffin embedding, followed by cutting of 5 μm thick sections. Hematoxylin and eosin (H&E) staining was performed on deparaffinized and rehydrated sections. Hematoxylin and eosin-stained slides were used for pathological scoring of inflammatory cell infiltrates as described below.
Staining for myelin basic protein (MBP) was performed on deparaffinized and rehydrated slides, followed by endogenous peroxidase blocking using Peroxidazed-1 (Biocare Medical PX968M, Concord, CA). Tissues were blocked with serum-free Protein Block (Dako X0909, Carpinteria, CA) and primary rat anti-mouse MBP antibody (Abcam Ab7349, Cambridge, MA) or control rat IgG (Vector Laboratories I-4000, Burlingame, CA) was added. Secondary rabbit anti-rat IgG antibody (Vector Laboratories AI-4001) was incubated at 1 μg/ml and signal amplification was performed using Rabbit EnVision HRP polymer R.T.U. (Dako K4002, Carpinteria, CA). Binding was detected using 3,3′-Diaminobenzidine (Dako K3467, Carpinteria, CA) followed by counterstaining with Hematoxylin Gill's no. 1 (Sigma-Aldrich GHS1128, St. Louis, MO) and Tacha's Bluing Solution (Biocare Medical HTBLU-MX, Concord, CA). The degree of demyelination was scored as described below.
Axonal damage was evaluated by staining for non-phosphorylated neurofilament heavy chain (SMI-32). Tissues were deparaffinized and rehydrated followed by heat-induced antigen retrieval in Decloaking Chamber™ NxGen (Biocare Medical DC2012, Concord, CA). After heat treatment, endogenous peroxidase was blocked using Peroxidazed-1 (Biocare Medical PX968M, Concord, CA). Tissues were blocked with Rodent Block M (Biocare Medical RBM961, Concord, CA) and incubated with primary antibody consisting of mouse anti-non-phosphorylated neurofilaments (BioLegend SMI-32P, Dedham, MA) or control mouse IgG1 (BD Pharmingen 557273, San Jose, CA) at 1 μg/ml. Secondary antibody containing anti-mouse IgG HRP R.T.U. (Biocare Medical MM510) was added and detected using 3,3′-Diaminobenzidine followed by counterstaining with Hematoxylin Gill's no. 1 and Tacha's Bluing Solution. SMI-32 stained slides were used for pathological scoring of axonal damage.
Inflammation, myelin loss and axonal damage were all graded by a pathologist blinded to treatment using a scale of 0-5 based on the approximate percentage of tissue involved with 0 = none, 1 = minimal (less than 5.0%), 2 = mild (5-10%), 3 = moderate (10-25%), 4 = severe (25-50%), and 5 = marked (N 50%).
Electrophysiology
Spinal motor evoked potential (SMEP) recording was performed and after the initiation of treatment with anti-muCD52 or vehicle. The mice were deeply anesthetized with ketamine/xylazine (50/2.86 mg/ml, i.p.) and placed on a heat blanket to maintain body temperature at 34°C. To limit movement-related artifacts due to electrical stimulation-induced muscle twitch, the animals' four limbs were restrained with tape. Laminectomy was then performed to expose the C3 region of the spinal cord for placement of the stimulating electrode (platinum microelectrode). A monopolar 27 gauge (g) needle reference electrode was placed under the skin above the third digit of each foot and a monopolar 27 g needle electrode was inserted into the gastrocnemius muscle of the corresponding hind limb for recording. Then, another monopolar 27 g needle ground electrode was placed under the skin of the lower back.
To induce SMEPs, a 100 μs pulse of constant current was generated by a Digitimer DS3 stimulus isolator and delivered to the spinal cord C3 region every 30s through the stimulating electrode. The SMEP was recorded from the gastrocnemius muscle of both hind limbs and filtered through a 300 Hz-1 kHz bandpass filter. The filtered signal was then encoded in the PowerLab data acquisition system and analyzed with LabChart software.
The input-output functions were generated for each animal by varying the intensity of stimulus pulses (using the amplitude dial on the stimulus isolator) in step increases (i.e. 0.5 mA, 1 mA, 1.5 mA, 2 mA, 2.5 mA, 3 mA, 3.5 mA, 4 mA). The responses were recorded for 1 min at each stimulus intensity. The largest threshold SMEP evoked by the lowest stimulus intensity was recorded for another 5 min for further quantification. The SMEP amplitude was measured between the first negative and the first positive peaks, whereas the SMEP latency was measured from the stimulus artifact to the first negative peak of the SMEP.
Results
Development and characterization of a novel anti-muCD52 antibody
To study the mechanism of action of anti-CD52 therapy in EAE mouse models of MS, a murine IgG2a CD52-specific monoclonal antibody with depleting activity was generated. The specificity of the antibody was first assessed by binding to CHO cells genetically engineered to express murine CD52 (muCD52). As demonstrated in Fig. 1A , staining with the anti-muCD52 antibody on the CHO-muCD52 cell line resulted in increased mean fluorescence intensity with little staining of the unmodified parental CHO-K1 cells, indicating the specificity of the antibody for muCD52. Affinity for CD52 was evaluated by surface plasmon resonance (SPR) and found to be sub-nanomolar for CD52 peptide (data not shown). We next evaluated the expression of muCD52 on immune cell populations including T cells (CD4 + , CD8 + and Treg), B cells, natural killer (NK) cells and neutrophils (Fig. 1B) . Murine CD52 expression was detected on 100% of the cells in each individual population, with T cells demonstrating the highest levels of expression, B cells expressing slightly lower levels of muCD52 and low levels of expression observed on NK cells. This expression pattern is similar to that observed for human CD52 in patients and human CD52 transgenic mice, with the exception of neutrophils which exhibited intermediate levels of muCD52 compared to low or undetectable levels for human CD52. (Elsner et al., 1996; Hu et al., 2009; Rao et al., 2012) . We next investigated the ability of the anti-muCD52 antibody to mediate lymphocyte depletion in vivo. Mice were injected i.v. with 10 mg/kg anti-muCD52, and three days later the numbers of lymphocytes in the spleen were quantified by flow cytometry. As expected, CD4 and CD8 T cells demonstrated the highest level of depletion (reduction of approximately 90%) followed by B cells and NK cells (reductions of 69% and 35%, respectively) (Fig. 1C) . The repopulation of these cell types was also evaluated longitudinally in peripheral blood. In this context, animals were treated with 5 daily doses of anti-muCD52 (10 mg/kg) to more closely resemble the dosing regimen used for alemtuzumab in MS patients. All cell types demonstrated similar repopulation kinetics with a return to baseline levels around day 100 posttreatment with anti-muCD52 (Fig. 1D ). This pattern is slightly different from what is observed after alemtuzumab treatment in MS patients or in alemtuzumab-treated human CD52 transgenic mice where B cell repopulation appears to occur more rapidly than T cell repopulation (Cox et al., 2005; Hu et al., 2009 ). Overall, these data demonstrate that the monoclonal antibody generated against muCD52 displays binding and depleting characteristics similar to those exhibited by alemtuzumab for human CD52.
Reduction of disease severity by anti-muCD52 treatment in EAE mouse models
The ability of the anti-muCD52 antibody to mediate lymphocyte depletion and the relatively long repopulation kinetics mimic treatment with alemtuzumab and afforded the opportunity to evaluate the therapeutic activity of anti-muCD52 treatment in EAE mouse models of MS. The anti-muCD52 antibody was first tested in the commonly used C57BL/6 EAE model in which disease is induced by immunization with myelin oligodendrocyte glycoprotein (MOG) peptide. Mice with early disease symptoms (mean clinical score of~1) were treated with a 5-day course of 10 mg/kg anti-muCD52 or vehicle delivered s.c. on days 12 through 16 after immunization. Reversal of disease symptoms was observed as early as 2 days following the initiation of treatment with anti-muCD52 and was maintained until the end of the study (day 40) without any further treatment ( Fig. 2A) . In contrast, control animals treated with vehicle continued to worsen, displaying an average disease score of~2.5 by day 20 post-disease induction.
In addition to the MOG 35-55 -induced disease model, C57BL/6 mice were also immunized with MOG 1-121 peptide containing the (Fig. 2B) . Disease in this model has been reported to involve the contribution of both B and T lymphocytes compared to MOG 35-55 which primarily stimulates T cells (Huntington et al., 2006) . Animals with early disease symptoms were treated with a single 5-day course of anti-muCD52 or vehicle s.c. (days 12-16 post-EAE induction) and, in this model as well, treatment with anti-muCD52 produced a reversal of symptoms and sustained inhibition of disease until the end of the study (day 40). As expected, animals receiving the vehicle developed significant, persistent disability.
Treatment with anti-muCD52 also provided a similar benefit in the SJL model of relapsing remitting MS (Fig. 2C ). In this model, SJL mice were immunized with PLP 139-153 and treated with a 5-day course of anti-muCD52 on days 12-16 following disease induction. Treatment with the antibody resulted in a reversal of disease symptoms and prevention of relapse compared to vehicle-treated mice (Fig. 2C) .
Overall, these results demonstrate the robust nature of antimuCD52 treatment in several models of EAE and parallel the long term control of disease observed in the majority of RRMS patients treated with alemtuzumab.
Impact of anti-muCD52 on pathogenic T cell responses in the spleen and CNS
To gain insight into the immunological impact of anti-CD52 treatment beyond what has been observed in the peripheral blood of MS patients, a longitudinal study was conducted in the MOG 35-55 EAE model to assess the numbers of CD4 + and CD8 + T cells in the spleen and CNS of diseased mice treated with anti-muCD52. As described above, C57BL/6 mice were treated with a 5 day course of anti-muCD52 antibody or vehicle on days 12-16 post-immunization with MOG peptide. Cohorts of animals were sacrificed on days 5, 10, 20, 30, or 40 following disease induction. As expected, treatment with antimuCD52 resulted in a reduction in the numbers of CD4 and CD8 T cells in the spleen (Fig. 3A, C) . This reduction in cell numbers was observed for the remainder of the study (Fig. 1D ). CD4 and CD8 T cell numbers in the brain and spinal cord were also assessed by flow cytometry (Fig. 3B,D ). An increase in the number of infiltrating CD4 and CD8 T cells was observed in the CNS of vehicle-treated EAE mice between days 10 and 20 post-disease induction. The kinetics of lymphocyte infiltration correlate with the onset and progression of disease symptoms observed in this model ( Fig. 2A) . Infiltrating T cells were retained in the CNS through day 40 likely contributing to the persistence of disease symptoms. In contrast, treatment with anti-muCD52 produced a sustained reduction in the number of CD4 and CD8 T cells in the CNS correlating with the inhibition of disease symptoms observed in treated mice. In addition to the assessment of total CD4 + T cells, the number of disease-causing MOG 35-55 reactive CD4 T cells in the spleens of treated animals was evaluated by intracellular cytokine staining (Fig. 3E, F ).
There was a significant reduction in the number of CD4 T cells that produced either IFNγ or IL-17 in response to ex vivo stimulation with MOG 35-55 peptide in anti-muCD52-treated mice compared to control mice. The difference was marked at day 20 when peak splenic reactivity occurred and was followed by a return to similarly low levels of cytokine-producing T cells at later time points in both groups (Fig. 3E,  F) . We were unable to study MOG 35-55 -induced cytokine production in CD4 T cells from the CNS as it was not possible to recover sufficient numbers of cells for this analysis. Levels of in vitro cytokine secretion by unfractionated splenocytes stimulated with MOG 35-55 peptide were also measured (Fig. 4A, B) . Stimulation of day 20 splenocytes from vehicle-treated EAE mice resulted in the release of several cytokines, most prominently IFN-γ. There was little or no cytokine release by splenocytes from anti-muCD52-treated mice.
Taken together, these results indicate that administration of antimuCD52 not only reduces the number of circulating T lymphocytes but also reduces the number of infiltrating T lymphocytes in the CNS of EAE mice and decreases the number of MOG-reactive CD4 T cells and overall cytokine production.
Reduction of CNS inflammation, demyelination and axonal damage by anti-muCD52 therapy
As demonstrated above, the therapeutic benefit provided by antimuCD52 treatment was associated with a reduction in pathogenic T cell responses and we next sought to characterize the resulting impact on CNS inflammation, demyelination and axonal damage. As in previous studies, mice were treated with a 5-day course of anti-muCD52 or vehicle on days 12-16 post-induction of disease with MOG 35-55 peptide. Five days later (day 21), cervical, thoracic, and lumbar regions of the spinal cord from each individual animal were collected and evaluated histologically for levels of inflammation (H&E staining), degree of myelination (anti-MBP staining) and axonal integrity (SMI-32 staining of damaged non-phosphorylated neurofilaments) as described in Materials and methods (Fig. 5) . In agreement with the flow cytometry results (Fig. 3) , significantly reduced immune cell infiltration was observed in all regions of the spinal cord in anti-muCD52-treated mice vs control mice (Fig. 5) . This was accompanied by a significant reduction in the degree of spinal cord demyelination and axonal damage. Collectively, these results demonstrate that treatment with anti-muCD52 strongly inhibited the development of CNS inflammation and concomitant demyelination and axonal damage.
Reversal of established disease and preservation of axonal function by anti-muCD52 treatment
Electrophysiology was used as a functional assessment of the benefit observed histologically in anti-muCD52-treated mice. In these studies, treatment was delayed until the mice developed more advanced disability and reached a disease score of 2 (Fig. 6A) . Administration of a 5 day course of anti-muCD52 at this stage of the disease still resulted in a reversal of symptoms compared to vehicle-treated animals (Fig. 6A) . To assess the functional impact of anti-muCD52 treatment on axonal conductance, the SMEP was evaluated in groups of mice prior to the start of treatment (day 0) and on day 10 after the first dose. Fig. 6B shows the representative SMEP waveforms obtained on day 10 after the initiation of treatment with vehicle or anti-muCD52 compared to the waveform from normal mice evaluated in parallel. There was a clear impairment of axonal conductance in vehicle-treated EAE mice compared to normal mice with partial correction in anti-muCD52-treated mice (Fig. 6B ). Fig. 6C shows the stimulus-response curves of the normal, vehicle-treated and anti-muCD52-treated mice. The curves graphically display the SMEP size in response to stimuli of increasing intensity. With gradual increases in stimulus intensity, increasing numbers of axons are progressively activated. In the normal mice, a low stimulus intensity (1 mA) was able to reach the maximal activation of the axons, whereas a higher stimulus intensity (1.5 mA) was required to activate all the axons in the vehicle-treated and anti-muCD52-treated groups. However, the SMEP in anti-muCD52-treated mice was significantly improved in response to the same stimuli above the threshold intensity when compared to the vehicle-treated group. Quantitative analysis showed that a significant reduction in SMEP peak amplitude in EAE mice (18.86 ± 3.55 μV), compared to normal mice (33.14 ± 3.06 μV), was already present before the start of treatment (day 0) and continued to worsen in EAE mice treated with vehicle (day 10) (12.00 ± 2.85 μV). In contrast, mice treated with anti-muCD52 did not experience further deterioration and largely maintained the same peak amplitude out to day 10 (22.75 ± 2.68 μV) (Fig. 6D) . In this and another study, EAE mice also displayed a small increase in peak latency prior to the start of treatment which remained present in vehicle-treated mice while peak latency was closer to normal in anti-muCD52-treated mice (not shown).
Overall, the results show a functional benefit in preservation of axonal conductance in EAE mice treated with anti-muCD52 as evidenced by electrophysiological assessment of SMEP peak amplitude and stimulusresponse curves.
Discussion
Studies of alemtuzumab's mechanism of action in RRMS patients have by necessity been largely limited to the examination of blood lymphocyte populations and imaging of the CNS. EAE mouse models of disease were used here to allow for a more extensive and direct assessment of the effects of anti-CD52 treatment on pathogenic T cells and on the CNS compartment in particular.
Due to the sequence disparity and lack of cross-reactivity between human and mouse CD52, a novel monoclonal antibody specific for murine CD52 (anti-muCD52) was generated to investigate the effects of anti-CD52 therapy in mouse EAE models. Analysis of antibody binding by flow cytometry and SPR confirmed the specificity and high affinity of the antibody for murine CD52 (Fig. 1) . The level of murine CD52 expression detected by the anti-muCD52 antibody showed a pattern similar to that of CD52 on human immune cells, with the highest levels of expression observed on T lymphocytes, slightly lower levels on B lymphocytes and little expression on NK cells. One difference was the level of CD52 on mouse neutrophils, which was elevated compared to what has been observed on human neutrophils that express little or no CD52 ( Fig. 1 ; Elsner et al., 1996) . Nevertheless, treatment of mice with anti-muCD52 resulted in immune cell depletion similar to what has been observed in MS patients and in human CD52 transgenic mice treated with alemtuzumab (Cox et al., 2005; Hu et al., 2009 ). There was robust depletion of lymphocytes and the pattern of repopulation also paralleled alemtuzumab observations although B and T lymphocytes appeared to recover to baseline levels at the same rate in contrast to the more rapid repopulation of B cells compared to T cells in alemtuzumabtreated RRMS patients and human CD52 transgenic mice (Cox et al., 2005; Hu et al., 2009) . Overall, the ability of anti-muCD52 to replicate the pattern of lymphocyte depletion followed by gradual repopulation supported its use in EAE mouse models.
To better understand the mechanism of action of anti-CD52 treatment, the therapeutic activity of the antibody was first tested in three different models of EAE reflecting different aspects of MS. EAE induced by MOG peptide in C57BL/6 mice represents a standard acute model of disease primarily driven by peptide-specific CD4 + cells while EAE induced by MOG 1-121 peptide is believed to involve the contribution of both T and B lymphocytes in the pathogenesis of the disease (Huntington et al., 2006; Stromnes and Goverman, 2006; Molnarfi et al., 2013) . Finally, EAE induced by PLP 139-151 peptide in SJL mice represents a standard model of relapsing-remitting disease involving T cell reactivity and epitope spreading (McRae et al., 1995) . Treatment with a single course of anti-muCD52 in mice with early symptoms achieved long term control of disease in all 3 models (Fig. 2) demonstrating efficacy against the different aspects of disease pathogenesis. Additional studies in the MOG 35-55 model also indicated that delayed administration of anti-muCD52 when the mice attained more significant disability with a disease score of 2 (full tail paralysis and hind limb paresis), was still efficacious and resulted in the reversal of disease symptoms (Fig. 6) . Importantly, long term monitoring of animals up to~day 90 in this treatment paradigm, demonstrated that control of disease was maintained without further retreatment in spite of complete lymphocyte repopulation in the blood and lymphoid organs (Supplemental Fig. 1 ). These results are aligned with the hypothesis that initial depletion of lymphocytes followed by rebalancing during repopulation is part of the mechanism of action of anti-CD52 therapy. The MOG 35-55 model was used to directly test whether depletion of pathogenic lymphocytes by anti-CD52 could in fact be linked to antiinflammatory effects in the CNS. As expected, treatment of diseased mice with anti-muCD52 antibody reduced the numbers of splenic CD4 and CD8 T cells (Fig. 3) . A significant reduction in the number of T lymphocytes infiltrating the CNS was also observed in contrast to the sustained elevation in the number of CD4 and CD8 T cells in the CNS of vehicle-treated mice (Fig. 3) . The observed reduction in the number of CNS-infiltrating T cells is most likely due to peripheral, rather than local, lymphocyte depletion given the generally poor CNS penetrance of antibodies. Intracellular cytokine staining after ex vivo stimulation with MOG 35-55 peptide was used to more specifically assess the impact of anti-muCD52 treatment on MOG-reactive, disease-causing CD4 + T cells. The numbers of IFNγ and IL-17-producing CD4 + T cells were measured as these cytokines have been shown to play a role in promoting disease in EAE as well as MS (Lock et al., 2002; Ishizu et al., 2005; Durelli et al., 2009; Jager et al., 2009; Kebir et al., 2009 ). The results confirmed that treatment with anti-muCD52 did reduce the number of these autoreactive, pathogenic T cells (Fig. 3E ). In addition, evaluation of inflammatory cytokine release by splenocytes stimulated with MOG peptide showed an overall reduction in cytokine production in antimuCD52-treated mice (Fig. 4) . These results are in agreement with the contention that treatment of RRMS patients with anti-CD52 can produce an anti-inflammatory effect in the CNS through depletion of pathogenic lymphocytes and alterations in the cytokine profile. An overall decrease in CD4 and CD8 T cells has also been observed in the peripheral blood of RRMS patients treated with alemtuzumab although an assessment of the frequency of autoreactive T cells has not yet been conducted. Similarly, a change in the cytokine profile of CD4 + T cells from alemtuzumab-treated patients towards a less inflammatory phenotype has been reported and postulated to play a role in the long term effect of the antibody (Zhang et al., 2013) .
Evidence from clinical studies is suggestive of a neuroprotective/ neuroreparative benefit in alemtuzumab-treated RRMS patients. An improvement in disability has been observed using different clinical assessments including EDSS, MSFC, and MSFC plus Sloan scores (Coles et al., 2012a,b; Hartung et al., 2012; Graves et al., 2014) . This improvement was maintained in the absence of ongoing treatment in most patients and was independent of the history of relapses i.e. not solely due to a direct anti-inflammatory effect (Fernández et al., 2013) . In addition, continued slowing in the rate of brain atrophy was also observed without re-treatment in the majority of patients over a 3 year period (Arnold et al., 2014) . The MOG 35-55 EAE model provided the opportunity to directly examine the CNS compartment to explore this aspect. First, the impact of anti-muCD52 treatment on the CNS was evaluated histologically. The spinal cord is more severely affected than the brain in this model and comprehensive examination of the cervical, thoracic and lumbar areas showed that treatment with antimuCD52 reduced the presence of inflammatory cell infiltrates (in agreement with the flow cytometry data) and dramatically reduced the level of demyelination and axonal damage (Fig. 5) . This improvement was observed 5 days after the final dose of treatment (Fig. 5) as well as up to 24 days post-treatment (not shown). These observations are in agreement with an immediate benefit of lymphocyte depletion followed by an environment that favors maintenance of CNS integrity.
In follow-up studies, electrophysiology was used as a functional assessment of the impact of anti-muCD52 treatment on axonal conductance. Importantly, in these studies, treatment was delayed until the mice reached a disease score of 2 and exhibited abnormal SMEP with decreased peak amplitude, slightly higher threshold stimulus for activation and a trend for increased peak latency. Reduced amplitude can largely be attributed to a decrease in the number and integrity of nerve fibers while increased latency typically results from inefficient conductance in demyelinated fibers. The results indicated that, while the peak amplitude of the SMEP continued to deteriorate in vehicletreated mice, the SMEP amplitude was maintained in anti-muCD52-treated mice (Fig. 6D) . These results are in line with the histological findings showing a reduction in damaged axons (Fig. 5) . There was also an apparent increase in latency in EAE mice compared to normal mice although the difference did not reach statistical significance in all studies. Anti-muCD52-treated mice showed a peak latency closer to normal compared to vehicle-treated mice, in agreement with the reduced demyelination observed histologically. However, given the small differences in latency, it is difficult to reach a firm conclusion regarding this parameter. Overall, these findings suggest that antimuCD52 treatment in mice with active disease protects the CNS against further damage and perhaps enables endogenous repair mechanisms resulting in long term reversal of disease symptoms and maintenance of axonal conductance.
Although the mechanism of action of alemtuzumab is not fully understood, the results from clinical and animal studies to date support the premise that the therapeutic benefit of the antibody involves the depletion of lymphocytes, including auto-reactive T cells, followed by rebalancing of the immune system during lymphocyte repopulation resulting in decreased CNS inflammation and protection of CNS integrity.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.jneuroim.2015.05.018.
